Cargando…

Elevation of arginine vasopressin levels following loop diuretic therapy as a prognostic indicator in heart failure

OBJECTIVE: To investigate the association between arginine vasopressin (AVP) levels and loop diuretic (LD) therapy in patients with heart failure and to determine if AVP levels are a prognostic indicator of treatment failure. METHODS: Patients with stable heart failure and reduced (< 40%) left ve...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitada, Shuichi, Kikuchi, Shohei, Sonoda, Hiroo, Yoshida, Atsuhiro, Ohte, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536742/
https://www.ncbi.nlm.nih.gov/pubmed/27789808
http://dx.doi.org/10.1177/0300060516663779
_version_ 1783254075690713088
author Kitada, Shuichi
Kikuchi, Shohei
Sonoda, Hiroo
Yoshida, Atsuhiro
Ohte, Nobuyuki
author_facet Kitada, Shuichi
Kikuchi, Shohei
Sonoda, Hiroo
Yoshida, Atsuhiro
Ohte, Nobuyuki
author_sort Kitada, Shuichi
collection PubMed
description OBJECTIVE: To investigate the association between arginine vasopressin (AVP) levels and loop diuretic (LD) therapy in patients with heart failure and to determine if AVP levels are a prognostic indicator of treatment failure. METHODS: Patients with stable heart failure and reduced (< 40%) left ventricular ejection fraction (LVEF) were divided into those treated with (LD) or without LD (NLD). The LD group was separated into subgroups of high (> 6.5 pg/dl) and low (≤ 6.5 pg/dl) AVP levels. The clinical and biochemical characteristics of the two groups were compared and the prognostic value of AVP levels in heart failure evaluated. RESULTS: Of the 63 patients enrolled into the study, 41 (65.1%) were in the LD group and 22 (34.9%) were in the NLD group. Despite no differences between groups in LVEF, creatinine clearance, or brain natriuretic peptide, the LD group had significantly higher AVP levels compared with the NLD group. A Cox proportional-hazards model showed that AVP was an independent predictor of adverse events. In addition, the elevation in AVP in the LD group was inversely correlated with an increase in free water clearance but not serum osmolality and was related to poor outcome. CONCLUSIONS: Elevated AVP levels in patients with heart failure who received LD therapy were associated with a poor prognosis. Loop diuretics may induce non-osmolar AVP release, which can worsen heart failure.
format Online
Article
Text
id pubmed-5536742
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-55367422017-10-03 Elevation of arginine vasopressin levels following loop diuretic therapy as a prognostic indicator in heart failure Kitada, Shuichi Kikuchi, Shohei Sonoda, Hiroo Yoshida, Atsuhiro Ohte, Nobuyuki J Int Med Res Clinical Reports OBJECTIVE: To investigate the association between arginine vasopressin (AVP) levels and loop diuretic (LD) therapy in patients with heart failure and to determine if AVP levels are a prognostic indicator of treatment failure. METHODS: Patients with stable heart failure and reduced (< 40%) left ventricular ejection fraction (LVEF) were divided into those treated with (LD) or without LD (NLD). The LD group was separated into subgroups of high (> 6.5 pg/dl) and low (≤ 6.5 pg/dl) AVP levels. The clinical and biochemical characteristics of the two groups were compared and the prognostic value of AVP levels in heart failure evaluated. RESULTS: Of the 63 patients enrolled into the study, 41 (65.1%) were in the LD group and 22 (34.9%) were in the NLD group. Despite no differences between groups in LVEF, creatinine clearance, or brain natriuretic peptide, the LD group had significantly higher AVP levels compared with the NLD group. A Cox proportional-hazards model showed that AVP was an independent predictor of adverse events. In addition, the elevation in AVP in the LD group was inversely correlated with an increase in free water clearance but not serum osmolality and was related to poor outcome. CONCLUSIONS: Elevated AVP levels in patients with heart failure who received LD therapy were associated with a poor prognosis. Loop diuretics may induce non-osmolar AVP release, which can worsen heart failure. SAGE Publications 2016-10-26 2016-12 /pmc/articles/PMC5536742/ /pubmed/27789808 http://dx.doi.org/10.1177/0300060516663779 Text en © The Author(s) 2016 http://creativecommons.org/licenses/by-nc/3.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Clinical Reports
Kitada, Shuichi
Kikuchi, Shohei
Sonoda, Hiroo
Yoshida, Atsuhiro
Ohte, Nobuyuki
Elevation of arginine vasopressin levels following loop diuretic therapy as a prognostic indicator in heart failure
title Elevation of arginine vasopressin levels following loop diuretic therapy as a prognostic indicator in heart failure
title_full Elevation of arginine vasopressin levels following loop diuretic therapy as a prognostic indicator in heart failure
title_fullStr Elevation of arginine vasopressin levels following loop diuretic therapy as a prognostic indicator in heart failure
title_full_unstemmed Elevation of arginine vasopressin levels following loop diuretic therapy as a prognostic indicator in heart failure
title_short Elevation of arginine vasopressin levels following loop diuretic therapy as a prognostic indicator in heart failure
title_sort elevation of arginine vasopressin levels following loop diuretic therapy as a prognostic indicator in heart failure
topic Clinical Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536742/
https://www.ncbi.nlm.nih.gov/pubmed/27789808
http://dx.doi.org/10.1177/0300060516663779
work_keys_str_mv AT kitadashuichi elevationofargininevasopressinlevelsfollowingloopdiuretictherapyasaprognosticindicatorinheartfailure
AT kikuchishohei elevationofargininevasopressinlevelsfollowingloopdiuretictherapyasaprognosticindicatorinheartfailure
AT sonodahiroo elevationofargininevasopressinlevelsfollowingloopdiuretictherapyasaprognosticindicatorinheartfailure
AT yoshidaatsuhiro elevationofargininevasopressinlevelsfollowingloopdiuretictherapyasaprognosticindicatorinheartfailure
AT ohtenobuyuki elevationofargininevasopressinlevelsfollowingloopdiuretictherapyasaprognosticindicatorinheartfailure